Rivervest Venture Management 13F annual report
Rivervest Venture Management is an investment fund managing more than $6.82 billion ran by Sivan Weitzman. There are currently 4 companies in Mrs. Weitzman’s portfolio. The largest investments include Reneo Pharmaceuticals, Inc. and Spruce Bioscience, Inc., together worth $5.35 billion.
$6.82 billion Assets Under Management (AUM)
As of 17th July 2024, Rivervest Venture Management’s top holding is 2,534,220 shares of Reneo Pharmaceuticals, Inc. currently worth over $3.83 billion and making up 56.1% of the portfolio value.
In addition, the fund holds 2,936,281 shares of Spruce Bioscience, Inc. worth $1.52 billion.
The third-largest holding is Xilio Therapeutics, Inc. worth $1.37 billion and the next is Vapotherm Inc worth $112 million, with 52,881 shares owned.
Currently, Rivervest Venture Management's portfolio is worth at least $6.82 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Rivervest Venture Management
The Rivervest Venture Management office and employees reside in St. Louis, Missouri. According to the last 13-F report filed with the SEC, Sivan Weitzman serves as the Chief Financial Officer at Rivervest Venture Management.
One of the smallest hedge funds
The two most similar investment funds to Rivervest Venture Management are Invesco Asset Management and Qcm Cayman. They manage $6.83 billion and $6.85 billion respectively.
Sivan Weitzman investment strategy
Rivervest Venture Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 1.6% of
the total portfolio value.
The fund focuses on investments in the United States as
25.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
25% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $43.8 million.
The complete list of Rivervest Venture Management trades based on 13F SEC filings
These positions were updated on July 24th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Reneo Pharmaceuticals, Inc. |
No change
2,534,220
|
$3,826,672,000 | 56.07% |
| Spruce Bioscience, Inc. |
No change
2,936,281
|
$1,520,114,000 | 22.27% |
| Xilio Therapeutics, Inc. |
No change
1,441,444
|
$1,365,768,000 | 20.01% |
| Vapotherm Inc |
No change
52,881
|
$112,282,000 | 1.65% |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||
Hedge funds similar to Rivervest Venture Management
- Foresight Wealth Management
- Rayliant Investment Research
- B. Metzler Seel. Sohn & Co. Ag
- Vulcan Value Partners
- Timessquare Capital Management
- Qcm Cayman
- Invesco Asset Management
- Ruane, Cunniff & Goldfarb L.P.
- Thrivent Investment Management
- Columbia Wanger Asset Management
- Aegon Asset Management Uk PLC
- The Prudential Insurance Of America
- Cornell University
- Marshall & Ilsley